In Reply to Kahvecioglu et al.

[1]  G. Yazici,et al.  In Regard to Liveringhouse et al. , 2023, International journal of radiation oncology, biology, physics.

[2]  P. Johnstone,et al.  Neoadjuvant Simultaneous Integrated Boost Radiotherapy Improves Clinical Outcomes for Retroperitoneal Sarcoma: Neoadjuvant Simultaneous Integrated Boost Radiotherapy for Retroperitoneal Sarcoma. , 2023, International Journal of Radiation Oncology, Biology, Physics.

[3]  Jacob G. Scott,et al.  Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization , 2021, Translational oncology.

[4]  J. Blay,et al.  Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[5]  J. Blay,et al.  Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG , 2019, Clinical Cancer Research.

[6]  S. Bonvalot,et al.  Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group , 2016, Annals of surgery.

[7]  M. Bertagnolli,et al.  Locoregional Recurrence After Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Adverse Impact of Multifocal Disease and Potential Implications of Dose Escalation , 2013, Annals of Surgical Oncology.

[8]  J. Debus,et al.  Clinical Phase I/II trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis , 2012, BMC Cancer.